Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPNzVRR1I3NEkySHJVcHBNVDNZcWFpSkZxeWwyUFZPb0V2Z2xON2p2N0dfV3oyNFFJaUx3MTR4cll0dndYbFRsS09LNklPazZwY1ZPdFo4LTRfNkF6SGJwX1NUdkgxZXdWcjVpLXZ5TUZEblhwN3R0eFNDSFV3WGFnWHkyU3VUOFE3Wjc4Qmh4MXBYaGJzXzlLdFF2cmlxTFRTaUIwMWN6MEdlWENVRm01Z3RoXzJOeVlKYnhkX1FnRmFWSkV2c3lSR09FZ0N4RTkyemM1UDZSd3dfT1AyZHE0?oc=5" target="_blank">Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Novo Nordisk's CagriSema achieved a 23% weight loss over 84 weeks, compared to 25.5% with Eli Lilly's tirzepatide, failing to meet the primary endpoint in a head-to-head trial.

Novo Nordisk's CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to Eli Lilly’s tirzepatide in reducing body weight.

Novo Nordisk's CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for Eli Lilly's tirzepatide, failing to meet the primary endpoint in a head-to-head trial.

Novo Nordisk's experimental obesity medication CagriSema did not meet a primary endpoint in an open-label head-to-head trial, leading to a significant drop in the company's shares.

Novo Nordisk's stock reached a 52-week low after its experimental obesity drug CagriSema failed to meet the primary endpoint in a trial against Eli Lilly's tirzepatide.